Metagenomi To Regain Full Development Rights To Its Wholly-Owned Base Editing And Rigs Systems
Portfolio Pulse from Benzinga Newsdesk
Metagenomi, Inc. (NASDAQ:MGX) has regained full global rights to its gene editing technologies, including base editors and RIGS, previously under exclusive rights with Moderna, Inc. The companies mutually agreed to terminate their collaboration on the PH1 program, returning all rights to Metagenomi. This move allows Metagenomi to advance its technologies in areas like Alpha-1 antitrypsin deficiency and Wilson's disease, leveraging its expanded gene editing toolbox and in-house manufacturing capabilities. Moderna remains a shareholder in Metagenomi.
May 01, 2024 | 8:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Metagenomi regains full rights to its gene editing technologies, ending its collaboration with Moderna. This strategic move allows for the advancement of its technologies in critical disease areas.
Regaining full development rights to its gene editing technologies could significantly enhance Metagenomi's ability to innovate and commercialize its products, potentially leading to positive market reception and increased investor confidence.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100